{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T11:07:53Z","timestamp":1791025673560,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,8,21]],"date-time":"2013-08-21T00:00:00Z","timestamp":1377043200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s13277-013-1043-1","type":"journal-article","created":{"date-parts":[[2013,8,20]],"date-time":"2013-08-20T00:56:37Z","timestamp":1376960197000},"page":"323-332","source":"Crossref","is-referenced-by-count":16,"title":["Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model"],"prefix":"10.1007","volume":"35","author":[{"given":"Si-Zeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Dong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,21]]},"reference":[{"key":"1043_CR1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argil\u00e9s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793\u20139.","journal-title":"Clin Nutr"},{"key":"1043_CR2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale MJ. Mechanisms of cancer cachexia. Pysiol Rev. 2009;89:381\u2013410.","journal-title":"Pysiol Rev"},{"key":"1043_CR3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1159\/000073337","volume":"21","author":"JA Palesty","year":"2003","unstructured":"Palesty JA, Dudrick SJ. What we have learned about cachexia in gastrointestinal cancer. Dig Dis. 2003;21:198\u2013213.","journal-title":"Dig Dis"},{"key":"1043_CR4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc927","volume":"2","author":"MJ Tisdale","year":"2002","unstructured":"Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862\u201371.","journal-title":"Nat Rev Cancer"},{"key":"1043_CR5","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.biocel.2004.10.017","volume":"37","author":"J Khal","year":"2005","unstructured":"Khal J, Hine AV, Fearon KCH, Dejong CHC, Tisdale MJ. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol. 2005;37:2196\u2013206.","journal-title":"Int J Biochem Cell Biol"},{"key":"1043_CR6","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.251541198","volume":"98","author":"MD Gomes","year":"2001","unstructured":"Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001;98:14440\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1043_CR7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1065874","volume":"294","author":"SC Bodine","year":"2001","unstructured":"Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001;294:1704\u20138.","journal-title":"Science"},{"key":"1043_CR8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0959-8049(94)00344-5","volume":"31","author":"P Daneryd","year":"1995","unstructured":"Daneryd P, Hafstrom L, Svanberg E, Karlberg I. Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur J Cancer. 1995;31:97\u2013103.","journal-title":"Eur J Cancer"},{"key":"1043_CR9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/qjmed\/hcm095","volume":"100","author":"AA Sayer","year":"2007","unstructured":"Sayer AA, Syddall HE, Dennison EM, Martin HJ, Phillips DI, Cooper C, et al. Grip strength and the metabolic syndrome: findings from the Hertfordshire Cohort Study. QJM. 2007;100:707\u201313.","journal-title":"QJM"},{"key":"1043_CR10","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1093\/ndt\/gfm204","volume":"22","author":"SW Lee","year":"2007","unstructured":"Lee SW, Park GH, Lee SW, Song JH, Hong KC, Kim MJ. Insulin resistance and muscle wasting in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant. 2007;22:2554\u201362.","journal-title":"Nephrol Dial Transplant"},{"key":"1043_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cger.2008.03.005","volume":"24","author":"JE Morley","year":"2008","unstructured":"Morley JE. Diabetes and aging: epidemiologic overview. Clin Geriatr Med. 2008;24:395\u2013405.","journal-title":"Clin Geriatr Med"},{"key":"1043_CR12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ijc.24784","volume":"126","author":"ML Asp","year":"2010","unstructured":"Asp ML, Tian M, Wendel AA, Belury MA. Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice. Int J Cancer. 2010;126:756\u201363.","journal-title":"Int J Cancer"},{"key":"1043_CR13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1677\/JOE-10-0341","volume":"208","author":"SZ Chen","year":"2011","unstructured":"Chen SZ, Qiu ZG. Combined treatment with GH, insulin, and indomethacin alleviates cancer cachexia in a mouse model. J Endocrinol. 2011;208:131\u20136.","journal-title":"J Endocrinol"},{"key":"1043_CR14","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-06-2720","volume":"13","author":"K Lundholm","year":"2007","unstructured":"Lundholm K, K\u00f6rner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, et al. Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning. Clin Cancer Res. 2007;13:2699\u2013706.","journal-title":"Clin Cancer Res"},{"key":"1043_CR15","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/cbt.12.11.18134","volume":"12","author":"ML Asp","year":"2011","unstructured":"Asp ML, Tian M, Kliewer KL, Belury MA. Rosiglitazone delayed weight loss and anorexia while attenuating adipose depletion in mice with cancer cachexia. Cancer Biol Ther. 2011;12:957\u201365.","journal-title":"Cancer Biol Ther"},{"key":"1043_CR16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1464-5491.2009.02897.x","volume":"27","author":"JS Nam","year":"2010","unstructured":"Nam JS, Nam JY, Yoo JS, Cho M, Park JS, Ahn CW, et al. The effect of rosiglitazone on insulin sensitivity and mid-thigh low-density muscle in patients with type 2 diabetes. Diabet Med. 2010;27:30\u20136.","journal-title":"Diabet Med"},{"key":"1043_CR17","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bjc.6602725","volume":"93","author":"PM Sanders","year":"2005","unstructured":"Sanders PM, Russell ST, Tisdale MJ. Angiotensin II directly induces muscle protein catabolism through the ubiquitin-proteasome proteolytic pathway and may play a role in cancer cachexia. Br J Cancer. 2005;93:425\u201334.","journal-title":"Br J Cancer"},{"key":"1043_CR18","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI118698","volume":"97","author":"M Brink","year":"1996","unstructured":"Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996;97:2509\u201316.","journal-title":"J Clin Invest"},{"key":"1043_CR19","doi-asserted-by":"crossref","first-page":"35137","DOI":"10.1074\/jbc.M601320200","volume":"281","author":"Y Wei","year":"2006","unstructured":"Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2006;281:35137\u201346.","journal-title":"J Biol Chem"},{"key":"1043_CR20","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S0140-6736(03)12892-9","volume":"361","author":"SD Anker","year":"2003","unstructured":"Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077\u201383.","journal-title":"Lancet"},{"key":"1043_CR21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1388-9842(00)00146-X","volume":"3","author":"AO Adigun","year":"2001","unstructured":"Adigun AO, Ajayi AA. The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia. Eur J Heart Fail. 2001;3:359\u201363.","journal-title":"Eur J Heart Fail"},{"key":"1043_CR22","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/S0140-6736(02)08024-8","volume":"359","author":"G Onder","year":"2002","unstructured":"Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002;359:926\u201330.","journal-title":"Lancet"},{"key":"1043_CR23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13539-012-0072-8","volume":"3","author":"N Schanze","year":"2012","unstructured":"Schanze N, Springer J. Evidence for an effect of ACE inhibitors on cancer cachexia. J Cachex Sarcopenia Muscle. 2012;3:139.","journal-title":"J Cachex Sarcopenia Muscle"},{"key":"1043_CR24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1440-1746.2006.04797.x","volume":"22","author":"JH Neo","year":"2007","unstructured":"Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C. Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol. 2007;22:577\u201384.","journal-title":"J Gastroenterol Hepatol"},{"key":"1043_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00520-009-0722-3","volume":"18","author":"G Mantovani","year":"2010","unstructured":"Mantovani G, Madeddu C. Cancer cachexia: medical management. Support Care Cancer. 2010;18:1\u20139.","journal-title":"Support Care Cancer"},{"key":"1043_CR26","first-page":"490","volume":"21","author":"W Zhou","year":"2004","unstructured":"Zhou W, Jiang ZW, Jiang J, Li JS. The establishment of one kind of animal model of cancer cachexia. Chin J Exp Surg. 2004;21:490\u20131 (in Chinese).","journal-title":"Chin J Exp Surg"},{"key":"1043_CR27","first-page":"270","volume":"14","author":"YJ Nai","year":"2007","unstructured":"Nai YJ, Jiang ZW, Wang ZM, Li JS. Effect of nuclear factor-\u03baB inhibitor on cancer cachexia. J Parenter Enteral Nutr. 2007;14:270\u20134 (in Chinese).","journal-title":"J Parenter Enteral Nutr"},{"key":"1043_CR28","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0344-0338(11)81095-2","volume":"189","author":"W Remmele","year":"1993","unstructured":"Remmele W, Schicketanz KH. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract. 1993;189:862\u20136.","journal-title":"Pathol Res Pract"},{"key":"1043_CR29","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B","volume":"89","author":"RA Soslow","year":"2000","unstructured":"Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer. 2000;89:2637\u201345.","journal-title":"Cancer"},{"key":"1043_CR30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1072-7515(03)00382-X","volume":"197","author":"N MacDonald","year":"2003","unstructured":"MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE. Understanding and managing cancer cachexia. J Am Coll Surg. 2003;197:143\u201361.","journal-title":"J Am Coll Surg"},{"key":"1043_CR31","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0167-5273(02)00245-0","volume":"85","author":"S Haehling von","year":"2002","unstructured":"von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85:173\u201383.","journal-title":"Int J Cardiol"},{"key":"1043_CR32","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1207\/S15327914NC3701_4","volume":"37","author":"P O\u2019Gorman","year":"2000","unstructured":"O\u2019Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37:36\u201340.","journal-title":"Nutr Cancer"},{"key":"1043_CR33","doi-asserted-by":"crossref","first-page":"5830","DOI":"10.1210\/jcem.86.12.8107","volume":"86","author":"CG MacIntosh","year":"2001","unstructured":"MacIntosh CG, Morley JE, Wishart J, Morris H, Jansen JB, Horowitz M, et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concentrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab. 2001;86:5830\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1043_CR34","first-page":"191","volume":"13","author":"W Steinborn","year":"2003","unstructured":"Steinborn W, Ander SD. Cardiac cachexia: pathophysiology and clinical implications. Basic Appl Myol. 2003;13:191\u2013201.","journal-title":"Basic Appl Myol"},{"key":"1043_CR35","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ijc.1332","volume":"93","author":"I Bosaeus","year":"2001","unstructured":"Bosaeus I, Daneryd P, Svanberg E, Lundholm K. Dietary intake and resting energy expenditure in relation to weight loss in unselected cancer patients. Int J Cancer. 2001;93:380\u20133.","journal-title":"Int J Cancer"},{"key":"1043_CR36","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2407-10-363","volume":"10","author":"P Aulino","year":"2010","unstructured":"Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer. 2010;10:363.","journal-title":"BMC Cancer"},{"key":"1043_CR37","doi-asserted-by":"crossref","first-page":"H1565","DOI":"10.1152\/ajpheart.00146.2010","volume":"298","author":"T Yoshida","year":"2010","unstructured":"Yoshida T, Semprun-Prieto L, Sukhanov S, Delafontaine P. IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression. Am J Physiol Heart Circ Physiol. 2010;298:H1565\u201370.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1043_CR38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/MOG.0b013e3283347e77","volume":"26","author":"MJ Tisdale","year":"2010","unstructured":"Tisdale MJ. Cancer cachexia. Curr Opin Gastroenterol. 2010;26:146\u201351.","journal-title":"Curr Opin Gastroenterol"},{"key":"1043_CR39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/JES.0b013e3181f44f11","volume":"38","author":"JA Carson","year":"2010","unstructured":"Carson JA, Baltgalvis KA. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc Sport Sci Rev. 2010;38:168\u201376.","journal-title":"Exerc Sport Sci Rev"},{"key":"1043_CR40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0092-8674(00)81318-5","volume":"87","author":"PA Baeuerle","year":"1996","unstructured":"Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996;87:13\u201320.","journal-title":"Cell"},{"key":"1043_CR41","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2004.09.027","volume":"119","author":"D Cai","year":"2004","unstructured":"Cai D, Frantz JD, Tawa Jr NE, Melendez PA, Oh BC, Lidov HG, et al. IKKbeta\/NF-kappaB activation causes severe muscle wasting in mice. Cell. 2004;119:285\u201398.","journal-title":"Cell"},{"key":"1043_CR42","doi-asserted-by":"crossref","first-page":"C834","DOI":"10.1152\/ajpcell.00579.2003","volume":"287","author":"RW Jackman","year":"2004","unstructured":"Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Gell Physiol. 2004;287:C834\u201343.","journal-title":"Am J Physiol Gell Physiol"},{"key":"1043_CR43","first-page":"131","volume":"16","author":"D Coletti","year":"2006","unstructured":"Coletti D, Belli L, Adamo S. Cachexia: novel perspectives for an old syndrome. Basic Appl Myol. 2006;16:131\u20139.","journal-title":"Basic Appl Myol"},{"issue":"1","key":"1043_CR44","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1152\/ajpendo.90632.2008","volume":"297","author":"AH Remels","year":"2009","unstructured":"Remels AH, Langen RC, Gosker HR, Russell AP, Spaapen F, Voncken JW, et al. PPARgamma inhibits NF-kappaB-dependent transcriptional activation in skeletal muscle. Am J Physiol Endocrinol Metab. 2009;297(1):E174\u201383.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1043_CR45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.bbrc.2007.05.222","volume":"360","author":"YP Bai","year":"2007","unstructured":"Bai YP, Liu YH, Chen J, Song T, You Y, Tang ZY, et al. Rosiglitazone attenuates NF-kappaB-dependent ICAM-1 and TNF-alpha production caused by homocysteine via inhibiting ERK1\/2\/p38MAPK activation. Biochem Biophys Res Commun. 2007;360:20\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"1043_CR46","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bbrc.2005.08.203","volume":"336","author":"KC Choi","year":"2005","unstructured":"Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem Biophys Res Commun. 2005;336:747\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"1043_CR47","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1161\/01.CIR.0000161954.17870.5D","volume":"111","author":"A Harte","year":"2005","unstructured":"Harte A, McTernan P, Chetty R, Coppack S, Katz J, Smith S, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation. 2005;111:1954\u201361.","journal-title":"Circulation"},{"issue":"6 Pt 1","key":"1043_CR48","first-page":"E1033","volume":"258","author":"LC Fernandes","year":"1990","unstructured":"Fernandes LC, Machado UF, Nogueira CR, Carpinelli AR, Curi R. Insulin secretion in Walker 256 tumor cachexia. Am J Physiol. 1990;258(6 Pt 1):E1033\u20136.","journal-title":"Am J Physiol"},{"key":"1043_CR49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1046\/j.1365-2265.2002.01540.x","volume":"56","author":"AL Crown","year":"2002","unstructured":"Crown AL, Cottle K, Lightman SL, Falk S, Mohamed-Ali V, Armstrong L, et al. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated? Clin Endocrinol (Oxf). 2002;56:723\u201333.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1043_CR50","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/bjs.1800791240","volume":"79","author":"JL McCall","year":"1992","unstructured":"McCall JL, Tuckey JA, Parry BR. Serum tumor necrosis factor alpha and insulin resistance in gastrointestinal cancer. Br J Surg. 1992;79:1361\u20133.","journal-title":"Br J Surg"},{"key":"1043_CR51","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/endo.130.1.1727716","volume":"130","author":"CH Lang","year":"1992","unstructured":"Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43\u201352.","journal-title":"Endocrinology"},{"key":"1043_CR52","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1046\/j.1471-4159.2002.00899.x","volume":"81","author":"T Zander","year":"2002","unstructured":"Zander T, Kraus JA, Grommes C, Schlegel U, Feinstein D, Klockgether T, et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma. J Neurochem. 2002;81:1052\u201360.","journal-title":"J Neurochem"},{"key":"1043_CR53","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.HYP.0000035522.63647.D3","volume":"40","author":"S Goetze","year":"2002","unstructured":"Goetze S, Bungenstock A, Czupalla C, Eilers F, Stawowy P, Kintscher U, et al. Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR gamma-ligands. Hypertension. 2002;40:748\u201354.","journal-title":"Hypertension"},{"key":"1043_CR54","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diabetes.50.5.1083","volume":"50","author":"M Iwata","year":"2001","unstructured":"Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator\u2013activated receptor -gamma. Diabetes. 2001;50:1083\u201392.","journal-title":"Diabetes"},{"key":"1043_CR55","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.bcp.2009.12.013","volume":"79","author":"L Martinez","year":"2010","unstructured":"Martinez L, Berenguer M, Bruce MC, Marchand-Brustel Y, Govers R. Rosiglitazone increases cell surface GLUT4 levels in 3T3-L1 adipocytes through an enhancement of endosomal recycling. Biochem Pharmacol. 2010;79:1300\u20139.","journal-title":"Biochem Pharmacol"},{"key":"1043_CR56","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00592-008-0054-7","volume":"46","author":"SK Vijay","year":"2009","unstructured":"Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. Acta Diabetol. 2009;46:27\u201333.","journal-title":"Acta Diabetol"},{"key":"1043_CR57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/MCO.0b013e32835f816c","volume":"16","author":"A Cabassi","year":"2013","unstructured":"Cabassi A, Tedeschi S. Zinc-\u03b12-glycoprotein as a marker of fat catabolism in humans. Curr Opin Clin Nutr Metab Care. 2013;16:267\u201371.","journal-title":"Curr Opin Clin Nutr Metab Care"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-1043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-013-1043-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-013-1043-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T11:17:09Z","timestamp":1563707829000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-013-1043-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,21]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["1043"],"URL":"https:\/\/doi.org\/10.1007\/s13277-013-1043-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,21]]}}}